CRISM Therapeutics Corporation - Asset Resilience Ratio

Latest as of December 2023: 19.75%

CRISM Therapeutics Corporation (CRTX) has an Asset Resilience Ratio of 19.75% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CRISM Therapeutics Corporation current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

GBX945.03K

≈ $114.98 USD Cash + Short-term Investments

Total Assets

GBX4.79 Million

≈ $582.32 USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2009–2014)

This chart shows how CRISM Therapeutics Corporation's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CRISM Therapeutics Corporation total assets.

Liquid Assets Composition Over Time

This chart breaks down CRISM Therapeutics Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read CRISM Therapeutics Corporation total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX945.03K	19.75%
Total Liquid Assets	GBX945.03K	19.75%

Asset Resilience Insights

Good Liquidity Position: CRISM Therapeutics Corporation maintains a healthy 19.75% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

CRISM Therapeutics Corporation Industry Peers by Asset Resilience Ratio

Compare CRISM Therapeutics Corporation's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for CRISM Therapeutics Corporation (2009–2014)

The table below shows the annual Asset Resilience Ratio data for CRISM Therapeutics Corporation.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2014-12-31	22.41%	GBX4.73 Million ≈ $575.95	GBX21.12 Million ≈ $2.57K	-22.97pp
2013-12-31	45.37%	GBX8.22 Million ≈ $1.00K	GBX18.13 Million ≈ $2.21K	+23.38pp
2012-12-31	21.99%	GBX3.56 Million ≈ $433.17	GBX16.19 Million ≈ $1.97K	+15.94pp
2011-12-31	6.05%	GBX1.29 Million ≈ $156.66	GBX21.29 Million ≈ $2.59K	-5.31pp
2010-12-31	11.36%	GBX2.43 Million ≈ $295.77	GBX21.40 Million ≈ $2.60K	+8.81pp
2009-12-31	2.55%	GBX427.90K ≈ $52.06	GBX16.81 Million ≈ $2.05K	--

pp = percentage points

About CRISM Therapeutics Corporation

LSE:CRTX UK Biotechnology

Market Cap

$108.39K

GBX890.83 Million GBX

Market Cap Rank

#31480 Global

#1114 in UK

Share Price

GBX11.25

Change (1 day)

+0.00%

52-Week Range

GBX8.75 - GBX17.50

All Time High

GBX2425.08